Robert G. Finizio's most recent trade in ZyVersa Therapeutics Inc was a trade of 11,066 Stock Options done . Disclosure was reported to the exchange on July 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ZyVersa Therapeutics Inc | Robert G. Finizio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 11,066 | 11,066 | - | - | Stock Options | |
| ZyVersa Therapeutics Inc | Finizio G. Robert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 132 | 132 | - | - | Stock Options | |
| ZyVersa Therapeutics Inc | Robert G. Finizio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 29,781 | 29,781 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Robert G. Finizio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 19,854 | 19,854 | - | - | Stock Options (right to buy) | |
| ZyVersa Therapeutics Inc | Robert G. Finizio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 9,927 | 9,927 | - | - | Stock Options (right to buy) | |
| TherapeuticsMD Inc | Robert G. Finizio | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 1,493,333 | 1,493,333 | - | - | Performance Stock Units | |
| TherapeuticsMD Inc | Robert G. Finizio | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 746,667 | 746,667 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Robert G. Finizio | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 158,334 | 316,666 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Robert G. Finizio | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 158,334 | 18,059,334 (6%) | 0% | - | Common Stock | |
| TherapeuticsMD Inc | Robert G. Finizio | Director, CEO | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 10 May 2021 | 67,697 | 17,991,637 (6%) | 0% | 1.0 | 70,405 | Common Stock |